AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
View original at finance.yahoo.comAMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Preclinical data in leukemia models demonstrate promising anti-cancer activity and mechanistic differentiation from currently available therapies, establishing rationale for single-agent and combination use to overcome treatment resistance and enhance durability of remission
80% confidenceAcute myeloid leukemia remains one of the most difficult cancers to treat, and there is an urgent need for new mechanisms capable of changing the trajectory of this disease
80% confidenceThe adjacency of this program to Amgen's expertise in cancer biology will propel MLLT1/3-targeting medicines to clinical investigation for AML patients
80% confidenceAmgen expects to integrate Dark Blue Therapeutics into its existing research organization, further strengthening the company's early oncology discovery efforts
80% confidenceThe acquisition complements and extends Amgen's research in targeted protein degradation and leukemia therapeutics, advancing their strategy to invest early in rising medicines for novel therapeutic targets
80% confidence